Capricor Therapeutics (CAPR) Operating Leases (2021 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Operating Leases of $13.9 million for Q1 2026, up 3322.65% year-over-year from $407392.0 in Q1 2025, and down 2.63% quarter-over-quarter from $14.3 million in Q4 2025.
Capricor Therapeutics (CAPR) Operating Leases (2021 - 2026) Analysis & Trends
Capricor Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Operating Leases rose 3322.65% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (up 3322.65% YoY), while the FY2025 annual figure was $14.3 million, up 2223.55% from the prior year.
- Operating Leases for Q1 2026 stood at $13.9 million, down from $14.3 million in the prior quarter.
- The five-year high for Operating Leases was $14.4 million in Q3 2025, with the low at $194603.0 in Q2 2025.
- The 5-year median for Operating Leases is $1.7 million (2023), against an average of $3.6 million.
- The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 81.36% in 2025, then soared 3322.65% in 2026.
- Capricor Therapeutics' Operating Leases stood at $1.9 million in 2022, then declined by 20.83% to $1.5 million in 2023, then plunged by 58.55% to $616315.0 in 2024, then soared by 2223.55% to $14.3 million in 2025, then dropped by 2.63% to $13.9 million in 2026.
- Business Quant data shows CAPR's Operating Leases at $13.9 million in Q1 2026, $14.3 million in Q4 2025, and $14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.94 Mn |
| Dec 31, 2025 | 14.32 Mn |
| Sep 30, 2025 | 14.42 Mn |
| Jun 30, 2025 | 194,603.00 |
| Mar 31, 2025 | 407,392.00 |
| Dec 31, 2024 | 616,315.00 |
| Sep 30, 2024 | 834,889.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.45 Mn |